My paper of the month - Consequences of increasing waiting times for treatment with commercially available autologous CAR-T cells targeting CD19 on the one-year all cause- survival for patients with relapsed/ refractory diffuse large B cell lymphoma.
… times on overall mortality of chimeric antigen receptor T-Cell Therapy in large B-Cell lymphoma: a discrete event … times for treatment with commercially available autologous CAR-T cells targeting CD19 on the one-year all cause- … engineered to express a Chimeric Antigen Receptor (CAR) or CAR-T Cells represent a promising therapy for …